nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—DGUOK—trachea—thyroid cancer	0.0192	0.153	CbGeAlD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.0181	0.143	CbGpPWpGaD
Nelarabine—DGUOK—thyroid gland—thyroid cancer	0.0152	0.121	CbGeAlD
Nelarabine—DGUOK—head—thyroid cancer	0.0135	0.107	CbGeAlD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.0132	0.105	CbGpPWpGaD
Nelarabine—DCK—saliva-secreting gland—thyroid cancer	0.00948	0.0754	CbGeAlD
Nelarabine—DGUOK—lymph node—thyroid cancer	0.00945	0.0751	CbGeAlD
Nelarabine—POLA1—thyroid gland—thyroid cancer	0.00938	0.0746	CbGeAlD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—TCF7L1—thyroid cancer	0.00931	0.0737	CbGpPWpGaD
Nelarabine—ADA—thyroid gland—thyroid cancer	0.0087	0.0692	CbGeAlD
Nelarabine—ADA—head—thyroid cancer	0.00772	0.0614	CbGeAlD
Nelarabine—DCK—trachea—thyroid cancer	0.00731	0.0582	CbGeAlD
Nelarabine—POLA1—G1/S-Specific Transcription—CDK1—thyroid cancer	0.00704	0.0557	CbGpPWpGaD
Nelarabine—DCK—Doxorubicin—Epirubicin—thyroid cancer	0.00603	0.519	CbGdCrCtD
Nelarabine—POLA1—lymph node—thyroid cancer	0.00583	0.0464	CbGeAlD
Nelarabine—DCK—thyroid gland—thyroid cancer	0.00578	0.046	CbGeAlD
Nelarabine—DCK—Epirubicin—Doxorubicin—thyroid cancer	0.00558	0.481	CbGdCrCtD
Nelarabine—ADA—lymph node—thyroid cancer	0.00541	0.043	CbGeAlD
Nelarabine—DCK—head—thyroid cancer	0.00513	0.0408	CbGeAlD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—CDK1—thyroid cancer	0.00414	0.0328	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—NRG1—thyroid cancer	0.00371	0.0294	CbGpPWpGaD
Nelarabine—DCK—lymph node—thyroid cancer	0.00359	0.0286	CbGeAlD
Nelarabine—DGUOK—Metabolism—MINPP1—thyroid cancer	0.00336	0.0266	CbGpPWpGaD
Nelarabine—POLA1—Extension of Telomeres—TERT—thyroid cancer	0.00331	0.0262	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00331	0.0262	CbGpPWpGaD
Nelarabine—Adenosine triphosphate—AKT1—thyroid cancer	0.00317	1	CrCbGaD
Nelarabine—ADA—p73 transcription factor network—CDK1—thyroid cancer	0.00305	0.0241	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—NDUFA13—thyroid cancer	0.00286	0.0226	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—CHST14—thyroid cancer	0.00269	0.0213	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.00261	0.0206	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—CDK1—thyroid cancer	0.00219	0.0174	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—HPGD—thyroid cancer	0.00217	0.0171	CbGpPWpGaD
Nelarabine—Burning sensation—Epirubicin—thyroid cancer	0.00193	0.00263	CcSEcCtD
Nelarabine—Neuralgia—Epirubicin—thyroid cancer	0.00193	0.00263	CcSEcCtD
Nelarabine—Paralysis—Epirubicin—thyroid cancer	0.00193	0.00263	CcSEcCtD
Nelarabine—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00192	0.00262	CcSEcCtD
Nelarabine—Oedema—Vandetanib—thyroid cancer	0.00192	0.00262	CcSEcCtD
Nelarabine—Epistaxis—Sorafenib—thyroid cancer	0.00191	0.00261	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.00191	0.0151	CbGpPWpGaD
Nelarabine—Infection—Vandetanib—thyroid cancer	0.00191	0.0026	CcSEcCtD
Nelarabine—Nervous system disorder—Vandetanib—thyroid cancer	0.00188	0.00257	CcSEcCtD
Nelarabine—Thrombocytopenia—Vandetanib—thyroid cancer	0.00188	0.00256	CcSEcCtD
Nelarabine—Nystagmus—Epirubicin—thyroid cancer	0.00188	0.00256	CcSEcCtD
Nelarabine—Cyst—Doxorubicin—thyroid cancer	0.00185	0.00253	CcSEcCtD
Nelarabine—Urinary tract disorder—Sorafenib—thyroid cancer	0.0018	0.00245	CcSEcCtD
Nelarabine—Neuritis—Epirubicin—thyroid cancer	0.0018	0.00245	CcSEcCtD
Nelarabine—Connective tissue disorder—Sorafenib—thyroid cancer	0.00179	0.00244	CcSEcCtD
Nelarabine—Urethral disorder—Sorafenib—thyroid cancer	0.00179	0.00243	CcSEcCtD
Nelarabine—Neuralgia—Doxorubicin—thyroid cancer	0.00178	0.00243	CcSEcCtD
Nelarabine—Paralysis—Doxorubicin—thyroid cancer	0.00178	0.00243	CcSEcCtD
Nelarabine—Burning sensation—Doxorubicin—thyroid cancer	0.00178	0.00243	CcSEcCtD
Nelarabine—Pleural effusion—Epirubicin—thyroid cancer	0.00175	0.00239	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00175	0.00238	CcSEcCtD
Nelarabine—Nystagmus—Doxorubicin—thyroid cancer	0.00174	0.00237	CcSEcCtD
Nelarabine—Fungal infection—Epirubicin—thyroid cancer	0.00174	0.00237	CcSEcCtD
Nelarabine—Insomnia—Vandetanib—thyroid cancer	0.00173	0.00237	CcSEcCtD
Nelarabine—Paraesthesia—Vandetanib—thyroid cancer	0.00172	0.00235	CcSEcCtD
Nelarabine—Dyspnoea—Vandetanib—thyroid cancer	0.00171	0.00233	CcSEcCtD
Nelarabine—Cardiac disorder—Sorafenib—thyroid cancer	0.00169	0.00231	CcSEcCtD
Nelarabine—Decreased appetite—Vandetanib—thyroid cancer	0.00167	0.00227	CcSEcCtD
Nelarabine—Neuritis—Doxorubicin—thyroid cancer	0.00166	0.00227	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00166	0.00226	CcSEcCtD
Nelarabine—Fatigue—Vandetanib—thyroid cancer	0.00165	0.00226	CcSEcCtD
Nelarabine—Angiopathy—Sorafenib—thyroid cancer	0.00165	0.00225	CcSEcCtD
Nelarabine—Rigors—Epirubicin—thyroid cancer	0.00164	0.00224	CcSEcCtD
Nelarabine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00164	0.00224	CcSEcCtD
Nelarabine—Pain—Vandetanib—thyroid cancer	0.00164	0.00224	CcSEcCtD
Nelarabine—Constipation—Vandetanib—thyroid cancer	0.00164	0.00224	CcSEcCtD
Nelarabine—Petechiae—Epirubicin—thyroid cancer	0.00163	0.00222	CcSEcCtD
Nelarabine—Pleural effusion—Doxorubicin—thyroid cancer	0.00162	0.00221	CcSEcCtD
Nelarabine—Fungal infection—Doxorubicin—thyroid cancer	0.00161	0.00219	CcSEcCtD
Nelarabine—Blood disorder—Epirubicin—thyroid cancer	0.0016	0.00219	CcSEcCtD
Nelarabine—Mental disorder—Sorafenib—thyroid cancer	0.0016	0.00218	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—CDK1—thyroid cancer	0.00159	0.0126	CbGpPWpGaD
Nelarabine—Malnutrition—Sorafenib—thyroid cancer	0.00159	0.00216	CcSEcCtD
Nelarabine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00157	0.00214	CcSEcCtD
Nelarabine—Dysgeusia—Sorafenib—thyroid cancer	0.00155	0.00212	CcSEcCtD
Nelarabine—Rigors—Doxorubicin—thyroid cancer	0.00152	0.00207	CcSEcCtD
Nelarabine—Body temperature increased—Vandetanib—thyroid cancer	0.00152	0.00207	CcSEcCtD
Nelarabine—Abdominal pain—Vandetanib—thyroid cancer	0.00152	0.00207	CcSEcCtD
Nelarabine—Petechiae—Doxorubicin—thyroid cancer	0.00151	0.00206	CcSEcCtD
Nelarabine—POLA1—Telomere Maintenance—TERT—thyroid cancer	0.0015	0.0119	CbGpPWpGaD
Nelarabine—Blood disorder—Doxorubicin—thyroid cancer	0.00148	0.00202	CcSEcCtD
Nelarabine—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.00147	0.00201	CcSEcCtD
Nelarabine—Anaemia—Sorafenib—thyroid cancer	0.00147	0.002	CcSEcCtD
Nelarabine—Hypocalcaemia—Epirubicin—thyroid cancer	0.00146	0.002	CcSEcCtD
Nelarabine—Hyperuricaemia—Epirubicin—thyroid cancer	0.00144	0.00197	CcSEcCtD
Nelarabine—Leukopenia—Sorafenib—thyroid cancer	0.00142	0.00194	CcSEcCtD
Nelarabine—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00142	0.00193	CcSEcCtD
Nelarabine—Dysarthria—Epirubicin—thyroid cancer	0.00142	0.00193	CcSEcCtD
Nelarabine—Loss of consciousness—Sorafenib—thyroid cancer	0.00139	0.0019	CcSEcCtD
Nelarabine—Cough—Sorafenib—thyroid cancer	0.00138	0.00189	CcSEcCtD
Nelarabine—Asthenia—Vandetanib—thyroid cancer	0.00138	0.00188	CcSEcCtD
Nelarabine—Gait disturbance—Epirubicin—thyroid cancer	0.00137	0.00187	CcSEcCtD
Nelarabine—Coordination abnormal—Epirubicin—thyroid cancer	0.00136	0.00186	CcSEcCtD
Nelarabine—Blood uric acid increased—Epirubicin—thyroid cancer	0.00136	0.00186	CcSEcCtD
Nelarabine—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.00136	0.00186	CcSEcCtD
Nelarabine—Hypocalcaemia—Doxorubicin—thyroid cancer	0.00135	0.00185	CcSEcCtD
Nelarabine—Myalgia—Sorafenib—thyroid cancer	0.00135	0.00184	CcSEcCtD
Nelarabine—Arthralgia—Sorafenib—thyroid cancer	0.00135	0.00184	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.00134	0.0106	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—PTGS2—thyroid cancer	0.00134	0.0106	CbGpPWpGaD
Nelarabine—Hyperuricaemia—Doxorubicin—thyroid cancer	0.00134	0.00182	CcSEcCtD
Nelarabine—Diarrhoea—Vandetanib—thyroid cancer	0.00131	0.00179	CcSEcCtD
Nelarabine—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00131	0.00179	CcSEcCtD
Nelarabine—Dysarthria—Doxorubicin—thyroid cancer	0.00131	0.00179	CcSEcCtD
Nelarabine—Infection—Sorafenib—thyroid cancer	0.00129	0.00175	CcSEcCtD
Nelarabine—Gait disturbance—Doxorubicin—thyroid cancer	0.00127	0.00173	CcSEcCtD
Nelarabine—Nervous system disorder—Sorafenib—thyroid cancer	0.00127	0.00173	CcSEcCtD
Nelarabine—Dizziness—Vandetanib—thyroid cancer	0.00127	0.00173	CcSEcCtD
Nelarabine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00127	0.00173	CcSEcCtD
Nelarabine—Coordination abnormal—Doxorubicin—thyroid cancer	0.00126	0.00172	CcSEcCtD
Nelarabine—Blood uric acid increased—Doxorubicin—thyroid cancer	0.00126	0.00172	CcSEcCtD
Nelarabine—Neuropathy—Epirubicin—thyroid cancer	0.00126	0.00172	CcSEcCtD
Nelarabine—POLA1—Chromosome Maintenance—TERT—thyroid cancer	0.00125	0.00989	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—TPR—thyroid cancer	0.00124	0.00985	CbGpPWpGaD
Nelarabine—Anorexia—Sorafenib—thyroid cancer	0.00123	0.00168	CcSEcCtD
Nelarabine—Coma—Epirubicin—thyroid cancer	0.00122	0.00167	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PRKAR1A—thyroid cancer	0.00122	0.00969	CbGpPWpGaD
Nelarabine—Vomiting—Vandetanib—thyroid cancer	0.00122	0.00166	CcSEcCtD
Nelarabine—Neoplasm—Epirubicin—thyroid cancer	0.00121	0.00165	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—CCND1—thyroid cancer	0.00121	0.00957	CbGpPWpGaD
Nelarabine—Headache—Vandetanib—thyroid cancer	0.0012	0.00164	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.00119	0.00941	CbGpPWpGaD
Nelarabine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00118	0.00161	CcSEcCtD
Nelarabine—Hypertonia—Epirubicin—thyroid cancer	0.00117	0.0016	CcSEcCtD
Nelarabine—Neuropathy—Doxorubicin—thyroid cancer	0.00116	0.00159	CcSEcCtD
Nelarabine—Mental disability—Epirubicin—thyroid cancer	0.00116	0.00159	CcSEcCtD
Nelarabine—Sepsis—Epirubicin—thyroid cancer	0.00116	0.00159	CcSEcCtD
Nelarabine—Dyspnoea—Sorafenib—thyroid cancer	0.00115	0.00157	CcSEcCtD
Nelarabine—Nausea—Vandetanib—thyroid cancer	0.00114	0.00155	CcSEcCtD
Nelarabine—Coma—Doxorubicin—thyroid cancer	0.00113	0.00155	CcSEcCtD
Nelarabine—Decreased appetite—Sorafenib—thyroid cancer	0.00112	0.00153	CcSEcCtD
Nelarabine—Neoplasm—Doxorubicin—thyroid cancer	0.00112	0.00153	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00112	0.00152	CcSEcCtD
Nelarabine—ADA—Metabolism—MINPP1—thyroid cancer	0.00112	0.00883	CbGpPWpGaD
Nelarabine—Fatigue—Sorafenib—thyroid cancer	0.00112	0.00152	CcSEcCtD
Nelarabine—Constipation—Sorafenib—thyroid cancer	0.00111	0.00151	CcSEcCtD
Nelarabine—Pain—Sorafenib—thyroid cancer	0.00111	0.00151	CcSEcCtD
Nelarabine—Hypertonia—Doxorubicin—thyroid cancer	0.00109	0.00148	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.00109	0.00859	CbGpPWpGaD
Nelarabine—Sepsis—Doxorubicin—thyroid cancer	0.00108	0.00147	CcSEcCtD
Nelarabine—Mental disability—Doxorubicin—thyroid cancer	0.00108	0.00147	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—PCM1—thyroid cancer	0.00106	0.00841	CbGpPWpGaD
Nelarabine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00106	0.00144	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—NRAS—thyroid cancer	0.00104	0.00824	CbGpPWpGaD
Nelarabine—DCK—Metabolism—MINPP1—thyroid cancer	0.00103	0.00815	CbGpPWpGaD
Nelarabine—Body temperature increased—Sorafenib—thyroid cancer	0.00102	0.00139	CcSEcCtD
Nelarabine—Abdominal pain—Sorafenib—thyroid cancer	0.00102	0.00139	CcSEcCtD
Nelarabine—Hypoglycaemia—Epirubicin—thyroid cancer	0.000997	0.00136	CcSEcCtD
Nelarabine—Lethargy—Epirubicin—thyroid cancer	0.000993	0.00135	CcSEcCtD
Nelarabine—Pain in extremity—Epirubicin—thyroid cancer	0.000973	0.00133	CcSEcCtD
Nelarabine—Osteoarthritis—Epirubicin—thyroid cancer	0.000973	0.00133	CcSEcCtD
Nelarabine—POLA1—Mitotic M-M/G1 phases—TPR—thyroid cancer	0.000971	0.00769	CbGpPWpGaD
Nelarabine—ADA—Metabolism—NDUFA13—thyroid cancer	0.000949	0.00751	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000943	0.00747	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—SLC5A5—thyroid cancer	0.000931	0.00737	CbGpPWpGaD
Nelarabine—Asthenia—Sorafenib—thyroid cancer	0.000928	0.00127	CcSEcCtD
Nelarabine—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000922	0.00126	CcSEcCtD
Nelarabine—Lethargy—Doxorubicin—thyroid cancer	0.000919	0.00125	CcSEcCtD
Nelarabine—Ataxia—Epirubicin—thyroid cancer	0.000915	0.00125	CcSEcCtD
Nelarabine—Blood creatinine increased—Epirubicin—thyroid cancer	0.000911	0.00124	CcSEcCtD
Nelarabine—Dehydration—Epirubicin—thyroid cancer	0.000905	0.00123	CcSEcCtD
Nelarabine—Pain in extremity—Doxorubicin—thyroid cancer	0.0009	0.00123	CcSEcCtD
Nelarabine—Osteoarthritis—Doxorubicin—thyroid cancer	0.0009	0.00123	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—KRAS—thyroid cancer	0.000896	0.0071	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CHST14—thyroid cancer	0.000892	0.00706	CbGpPWpGaD
Nelarabine—Hypokalaemia—Epirubicin—thyroid cancer	0.000885	0.00121	CcSEcCtD
Nelarabine—Diarrhoea—Sorafenib—thyroid cancer	0.000885	0.00121	CcSEcCtD
Nelarabine—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000876	0.00119	CcSEcCtD
Nelarabine—DCK—Metabolism—NDUFA13—thyroid cancer	0.000876	0.00693	CbGpPWpGaD
Nelarabine—Muscular weakness—Epirubicin—thyroid cancer	0.000858	0.00117	CcSEcCtD
Nelarabine—Dizziness—Sorafenib—thyroid cancer	0.000856	0.00117	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—PPARG—thyroid cancer	0.000847	0.0067	CbGpPWpGaD
Nelarabine—Abdominal distension—Epirubicin—thyroid cancer	0.000846	0.00115	CcSEcCtD
Nelarabine—Ataxia—Doxorubicin—thyroid cancer	0.000846	0.00115	CcSEcCtD
Nelarabine—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000843	0.00115	CcSEcCtD
Nelarabine—Dehydration—Doxorubicin—thyroid cancer	0.000837	0.00114	CcSEcCtD
Nelarabine—DCK—Metabolism—CHST14—thyroid cancer	0.000823	0.00652	CbGpPWpGaD
Nelarabine—Vomiting—Sorafenib—thyroid cancer	0.000823	0.00112	CcSEcCtD
Nelarabine—Hypokalaemia—Doxorubicin—thyroid cancer	0.000819	0.00112	CcSEcCtD
Nelarabine—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000811	0.00111	CcSEcCtD
Nelarabine—Headache—Sorafenib—thyroid cancer	0.00081	0.00111	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000794	0.00629	CbGpPWpGaD
Nelarabine—Muscular weakness—Doxorubicin—thyroid cancer	0.000794	0.00108	CcSEcCtD
Nelarabine—Neutropenia—Epirubicin—thyroid cancer	0.000786	0.00107	CcSEcCtD
Nelarabine—Abdominal distension—Doxorubicin—thyroid cancer	0.000783	0.00107	CcSEcCtD
Nelarabine—DGUOK—Metabolism—RXRA—thyroid cancer	0.000782	0.00619	CbGpPWpGaD
Nelarabine—Nausea—Sorafenib—thyroid cancer	0.000768	0.00105	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—HRAS—thyroid cancer	0.000762	0.00603	CbGpPWpGaD
Nelarabine—Hyperglycaemia—Epirubicin—thyroid cancer	0.000758	0.00103	CcSEcCtD
Nelarabine—Pneumonia—Epirubicin—thyroid cancer	0.000754	0.00103	CcSEcCtD
Nelarabine—Infestation—Epirubicin—thyroid cancer	0.00075	0.00102	CcSEcCtD
Nelarabine—Infestation NOS—Epirubicin—thyroid cancer	0.00075	0.00102	CcSEcCtD
Nelarabine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000735	0.001	CcSEcCtD
Nelarabine—Stomatitis—Epirubicin—thyroid cancer	0.000731	0.000997	CcSEcCtD
Nelarabine—Neutropenia—Doxorubicin—thyroid cancer	0.000727	0.000992	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—TPR—thyroid cancer	0.000726	0.00575	CbGpPWpGaD
Nelarabine—ADA—Metabolism—HPGD—thyroid cancer	0.000719	0.00569	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000715	0.00566	CbGpPWpGaD
Nelarabine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000709	0.000967	CcSEcCtD
Nelarabine—Epistaxis—Epirubicin—thyroid cancer	0.000707	0.000964	CcSEcCtD
Nelarabine—Sinusitis—Epirubicin—thyroid cancer	0.000703	0.000959	CcSEcCtD
Nelarabine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000702	0.000957	CcSEcCtD
Nelarabine—Pneumonia—Doxorubicin—thyroid cancer	0.000698	0.000952	CcSEcCtD
Nelarabine—Infestation—Doxorubicin—thyroid cancer	0.000694	0.000946	CcSEcCtD
Nelarabine—Infestation NOS—Doxorubicin—thyroid cancer	0.000694	0.000946	CcSEcCtD
Nelarabine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00068	0.000927	CcSEcCtD
Nelarabine—Stomatitis—Doxorubicin—thyroid cancer	0.000676	0.000922	CcSEcCtD
Nelarabine—Hypoaesthesia—Epirubicin—thyroid cancer	0.00067	0.000913	CcSEcCtD
Nelarabine—Urinary tract disorder—Epirubicin—thyroid cancer	0.000665	0.000906	CcSEcCtD
Nelarabine—DCK—Metabolism—HPGD—thyroid cancer	0.000664	0.00525	CbGpPWpGaD
Nelarabine—Oedema peripheral—Epirubicin—thyroid cancer	0.000663	0.000904	CcSEcCtD
Nelarabine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000661	0.000902	CcSEcCtD
Nelarabine—Urethral disorder—Epirubicin—thyroid cancer	0.00066	0.0009	CcSEcCtD
Nelarabine—POLA1—Mitotic M-M/G1 phases—CDK1—thyroid cancer	0.000658	0.00521	CbGpPWpGaD
Nelarabine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000656	0.000895	CcSEcCtD
Nelarabine—Epistaxis—Doxorubicin—thyroid cancer	0.000654	0.000892	CcSEcCtD
Nelarabine—Sinusitis—Doxorubicin—thyroid cancer	0.000651	0.000888	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—TPR—thyroid cancer	0.000649	0.00514	CbGpPWpGaD
Nelarabine—Eye disorder—Epirubicin—thyroid cancer	0.000629	0.000858	CcSEcCtD
Nelarabine—Cardiac disorder—Epirubicin—thyroid cancer	0.000625	0.000852	CcSEcCtD
Nelarabine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00062	0.000845	CcSEcCtD
Nelarabine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000615	0.000839	CcSEcCtD
Nelarabine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000613	0.000837	CcSEcCtD
Nelarabine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000612	0.000835	CcSEcCtD
Nelarabine—Angiopathy—Epirubicin—thyroid cancer	0.000611	0.000833	CcSEcCtD
Nelarabine—Urethral disorder—Doxorubicin—thyroid cancer	0.00061	0.000833	CcSEcCtD
Nelarabine—Mediastinal disorder—Epirubicin—thyroid cancer	0.000607	0.000827	CcSEcCtD
Nelarabine—Chills—Epirubicin—thyroid cancer	0.000604	0.000824	CcSEcCtD
Nelarabine—POLA1—S Phase—CCND1—thyroid cancer	0.000602	0.00477	CbGpPWpGaD
Nelarabine—Mental disorder—Epirubicin—thyroid cancer	0.00059	0.000804	CcSEcCtD
Nelarabine—Malnutrition—Epirubicin—thyroid cancer	0.000586	0.000799	CcSEcCtD
Nelarabine—Eye disorder—Doxorubicin—thyroid cancer	0.000582	0.000794	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—PTEN—thyroid cancer	0.000581	0.0046	CbGpPWpGaD
Nelarabine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000578	0.000788	CcSEcCtD
Nelarabine—Dysgeusia—Epirubicin—thyroid cancer	0.000574	0.000782	CcSEcCtD
Nelarabine—Back pain—Epirubicin—thyroid cancer	0.000567	0.000773	CcSEcCtD
Nelarabine—Angiopathy—Doxorubicin—thyroid cancer	0.000565	0.000771	CcSEcCtD
Nelarabine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000561	0.000765	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.000559	0.00442	CbGpPWpGaD
Nelarabine—Chills—Doxorubicin—thyroid cancer	0.000559	0.000762	CcSEcCtD
Nelarabine—Vision blurred—Epirubicin—thyroid cancer	0.000552	0.000753	CcSEcCtD
Nelarabine—Mental disorder—Doxorubicin—thyroid cancer	0.000546	0.000744	CcSEcCtD
Nelarabine—Malnutrition—Doxorubicin—thyroid cancer	0.000542	0.000739	CcSEcCtD
Nelarabine—Anaemia—Epirubicin—thyroid cancer	0.000541	0.000739	CcSEcCtD
Nelarabine—Dysgeusia—Doxorubicin—thyroid cancer	0.000531	0.000724	CcSEcCtD
Nelarabine—Leukopenia—Epirubicin—thyroid cancer	0.000524	0.000715	CcSEcCtD
Nelarabine—Back pain—Doxorubicin—thyroid cancer	0.000524	0.000715	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000523	0.00414	CbGpPWpGaD
Nelarabine—Loss of consciousness—Epirubicin—thyroid cancer	0.000515	0.000702	CcSEcCtD
Nelarabine—Cough—Epirubicin—thyroid cancer	0.000511	0.000697	CcSEcCtD
Nelarabine—Vision blurred—Doxorubicin—thyroid cancer	0.000511	0.000697	CcSEcCtD
Nelarabine—Convulsion—Epirubicin—thyroid cancer	0.000508	0.000692	CcSEcCtD
Nelarabine—Anaemia—Doxorubicin—thyroid cancer	0.000501	0.000683	CcSEcCtD
Nelarabine—Myalgia—Epirubicin—thyroid cancer	0.000499	0.00068	CcSEcCtD
Nelarabine—Arthralgia—Epirubicin—thyroid cancer	0.000499	0.00068	CcSEcCtD
Nelarabine—Chest pain—Epirubicin—thyroid cancer	0.000499	0.00068	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PPARG—thyroid cancer	0.000494	0.00391	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000492	0.0039	CbGpPWpGaD
Nelarabine—Leukopenia—Doxorubicin—thyroid cancer	0.000485	0.000662	CcSEcCtD
Nelarabine—Confusional state—Epirubicin—thyroid cancer	0.000482	0.000658	CcSEcCtD
Nelarabine—Oedema—Epirubicin—thyroid cancer	0.000478	0.000652	CcSEcCtD
Nelarabine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000476	0.00065	CcSEcCtD
Nelarabine—Infection—Epirubicin—thyroid cancer	0.000475	0.000648	CcSEcCtD
Nelarabine—Cough—Doxorubicin—thyroid cancer	0.000473	0.000645	CcSEcCtD
Nelarabine—Convulsion—Doxorubicin—thyroid cancer	0.00047	0.000641	CcSEcCtD
Nelarabine—Nervous system disorder—Epirubicin—thyroid cancer	0.000469	0.00064	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000469	0.00371	CbGpPWpGaD
Nelarabine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000468	0.000639	CcSEcCtD
Nelarabine—Arthralgia—Doxorubicin—thyroid cancer	0.000461	0.000629	CcSEcCtD
Nelarabine—Chest pain—Doxorubicin—thyroid cancer	0.000461	0.000629	CcSEcCtD
Nelarabine—Myalgia—Doxorubicin—thyroid cancer	0.000461	0.000629	CcSEcCtD
Nelarabine—Anorexia—Epirubicin—thyroid cancer	0.000456	0.000622	CcSEcCtD
Nelarabine—Hypotension—Epirubicin—thyroid cancer	0.000447	0.000609	CcSEcCtD
Nelarabine—Confusional state—Doxorubicin—thyroid cancer	0.000446	0.000608	CcSEcCtD
Nelarabine—Oedema—Doxorubicin—thyroid cancer	0.000442	0.000603	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—CDK1—thyroid cancer	0.00044	0.00348	CbGpPWpGaD
Nelarabine—Infection—Doxorubicin—thyroid cancer	0.00044	0.000599	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000436	0.000594	CcSEcCtD
Nelarabine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000434	0.000592	CcSEcCtD
Nelarabine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000433	0.000591	CcSEcCtD
Nelarabine—Insomnia—Epirubicin—thyroid cancer	0.000432	0.00059	CcSEcCtD
Nelarabine—Paraesthesia—Epirubicin—thyroid cancer	0.000429	0.000586	CcSEcCtD
Nelarabine—Dyspnoea—Epirubicin—thyroid cancer	0.000426	0.000581	CcSEcCtD
Nelarabine—Somnolence—Epirubicin—thyroid cancer	0.000425	0.00058	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000423	0.00335	CbGpPWpGaD
Nelarabine—Anorexia—Doxorubicin—thyroid cancer	0.000422	0.000575	CcSEcCtD
Nelarabine—Decreased appetite—Epirubicin—thyroid cancer	0.000416	0.000567	CcSEcCtD
Nelarabine—Hypotension—Doxorubicin—thyroid cancer	0.000413	0.000564	CcSEcCtD
Nelarabine—ADA—Metabolism—TPR—thyroid cancer	0.000413	0.00327	CbGpPWpGaD
Nelarabine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000413	0.000563	CcSEcCtD
Nelarabine—Fatigue—Epirubicin—thyroid cancer	0.000412	0.000562	CcSEcCtD
Nelarabine—Pain—Epirubicin—thyroid cancer	0.000409	0.000558	CcSEcCtD
Nelarabine—Constipation—Epirubicin—thyroid cancer	0.000409	0.000558	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000409	0.00324	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PRKAR1A—thyroid cancer	0.000406	0.00322	CbGpPWpGaD
Nelarabine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000403	0.00055	CcSEcCtD
Nelarabine—Insomnia—Doxorubicin—thyroid cancer	0.0004	0.000546	CcSEcCtD
Nelarabine—Paraesthesia—Doxorubicin—thyroid cancer	0.000397	0.000542	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—TP53—thyroid cancer	0.000396	0.00314	CbGpPWpGaD
Nelarabine—Dyspnoea—Doxorubicin—thyroid cancer	0.000394	0.000538	CcSEcCtD
Nelarabine—Feeling abnormal—Epirubicin—thyroid cancer	0.000394	0.000537	CcSEcCtD
Nelarabine—Somnolence—Doxorubicin—thyroid cancer	0.000393	0.000536	CcSEcCtD
Nelarabine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000391	0.000533	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PTGS2—thyroid cancer	0.000389	0.00308	CbGpPWpGaD
Nelarabine—Decreased appetite—Doxorubicin—thyroid cancer	0.000385	0.000525	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000382	0.000521	CcSEcCtD
Nelarabine—Fatigue—Doxorubicin—thyroid cancer	0.000381	0.00052	CcSEcCtD
Nelarabine—DCK—Metabolism—TPR—thyroid cancer	0.000381	0.00302	CbGpPWpGaD
Nelarabine—Constipation—Doxorubicin—thyroid cancer	0.000378	0.000516	CcSEcCtD
Nelarabine—Pain—Doxorubicin—thyroid cancer	0.000378	0.000516	CcSEcCtD
Nelarabine—Abdominal pain—Epirubicin—thyroid cancer	0.000378	0.000516	CcSEcCtD
Nelarabine—Body temperature increased—Epirubicin—thyroid cancer	0.000378	0.000516	CcSEcCtD
Nelarabine—DCK—Metabolism—PRKAR1A—thyroid cancer	0.000375	0.00297	CbGpPWpGaD
Nelarabine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000365	0.000497	CcSEcCtD
Nelarabine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000362	0.000493	CcSEcCtD
Nelarabine—Body temperature increased—Doxorubicin—thyroid cancer	0.00035	0.000477	CcSEcCtD
Nelarabine—Abdominal pain—Doxorubicin—thyroid cancer	0.00035	0.000477	CcSEcCtD
Nelarabine—Asthenia—Epirubicin—thyroid cancer	0.000343	0.000468	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PTEN—thyroid cancer	0.000339	0.00268	CbGpPWpGaD
Nelarabine—Diarrhoea—Epirubicin—thyroid cancer	0.000327	0.000446	CcSEcCtD
Nelarabine—Asthenia—Doxorubicin—thyroid cancer	0.000317	0.000433	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—TERT—thyroid cancer	0.000317	0.00251	CbGpPWpGaD
Nelarabine—Dizziness—Epirubicin—thyroid cancer	0.000316	0.000431	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000314	0.00248	CbGpPWpGaD
Nelarabine—ADA—Metabolism—SLC5A5—thyroid cancer	0.000309	0.00245	CbGpPWpGaD
Nelarabine—Vomiting—Epirubicin—thyroid cancer	0.000304	0.000415	CcSEcCtD
Nelarabine—Diarrhoea—Doxorubicin—thyroid cancer	0.000303	0.000413	CcSEcCtD
Nelarabine—Headache—Epirubicin—thyroid cancer	0.0003	0.000409	CcSEcCtD
Nelarabine—Dizziness—Doxorubicin—thyroid cancer	0.000293	0.000399	CcSEcCtD
Nelarabine—DCK—Metabolism—SLC5A5—thyroid cancer	0.000285	0.00226	CbGpPWpGaD
Nelarabine—Nausea—Epirubicin—thyroid cancer	0.000284	0.000387	CcSEcCtD
Nelarabine—Vomiting—Doxorubicin—thyroid cancer	0.000281	0.000384	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000279	0.00221	CbGpPWpGaD
Nelarabine—Headache—Doxorubicin—thyroid cancer	0.000277	0.000378	CcSEcCtD
Nelarabine—Nausea—Doxorubicin—thyroid cancer	0.000263	0.000358	CcSEcCtD
Nelarabine—ADA—Metabolism—RXRA—thyroid cancer	0.00026	0.00206	CbGpPWpGaD
Nelarabine—DCK—Metabolism—RXRA—thyroid cancer	0.00024	0.0019	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000236	0.00186	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CCND1—thyroid cancer	0.000205	0.00162	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—AKT1—thyroid cancer	0.000195	0.00155	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CCND1—thyroid cancer	0.000183	0.00145	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PPARG—thyroid cancer	0.000164	0.0013	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PPARG—thyroid cancer	0.000151	0.0012	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PTGS2—thyroid cancer	0.000129	0.00102	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TP53—thyroid cancer	0.000121	0.000956	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PTGS2—thyroid cancer	0.000119	0.000943	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PTEN—thyroid cancer	0.000113	0.000891	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PTEN—thyroid cancer	0.000104	0.000822	CbGpPWpGaD
Nelarabine—ADA—Metabolism—AKT1—thyroid cancer	6.48e-05	0.000513	CbGpPWpGaD
Nelarabine—DCK—Metabolism—AKT1—thyroid cancer	5.98e-05	0.000474	CbGpPWpGaD
